AUTL vs. ATRA

Last updated Apr 1, 2026

Compare and contrast key facts about Autolus Therapeutics plc (AUTL) and Atara Biotherapeutics, Inc. (ATRA).

Performance

AUTL vs. ATRA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Autolus Therapeutics plc (AUTL) and Atara Biotherapeutics, Inc. (ATRA). The values are adjusted to include any dividend payments, if applicable.

AUTL vs. ATRA - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018
AUTL Autolus Therapeutics plc	-30.65%	-15.32%	-63.51%	238.95%	-63.39%	-41.95%	-32.27%	-59.81%	31.36%
ATRA Atara Biotherapeutics, Inc.	-73.85%	35.91%	3.82%	-84.37%	-79.19%	-19.71%	19.19%	-52.59%	-17.78%

Fundamentals

EPS AUTL : -$0.84 ATRA : $2.54
PS Ratio AUTL : 7.18 ATRA : 0.50
Total Revenue (TTM) AUTL : $51.13M ATRA : $120.77M
Gross Profit (TTM) AUTL : -$158.22M ATRA : $99.56M
EBITDA (TTM) AUTL : -$250.91M ATRA : $40.56M

Returns By Period

In the year-to-date period, AUTL achieves a -30.65% return, which is significantly higher than ATRA's -73.85% return.

AUTL

• 1D: 8.66%
• 1M: -19.30%
• YTD: -30.65%
• 6M: -15.34%
• 1Y: -10.97%
• 3Y*: -9.14%
• 5Y*: -25.24%
• 10Y*: —

ATRA

• 1D: 9.49%
• 1M: -12.73%
• YTD: -73.85%
• 6M: -66.99%
• 1Y: -20.37%
• 3Y*: -59.74%
• 5Y*: -58.25%
• 10Y*: -37.23%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

AUTL vs. ATRA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

AUTL

AUTL Risk / Return Rank: 36
AUTL Sharpe Ratio Rank: 35
AUTL Sortino Ratio Rank: 40
AUTL Omega Ratio Rank: 38
AUTL Calmar Ratio Rank: 32
AUTL Martin Ratio Rank: 34

ATRA

ATRA Risk / Return Rank: 36
ATRA Sharpe Ratio Rank: 33
ATRA Sortino Ratio Rank: 44
ATRA Omega Ratio Rank: 47
ATRA Calmar Ratio Rank: 30
ATRA Martin Ratio Rank: 28

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

AUTL vs. ATRA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Autolus Therapeutics plc (AUTL) and Atara Biotherapeutics, Inc. (ATRA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	AUTL	ATRA	Difference
Sharpe ratio Return per unit of total volatility	-0.13	-0.19	+0.05
Sortino ratio Return per unit of downside risk	0.41	0.58	-0.17
Omega ratio Gain probability vs. loss probability	1.05	1.09	-0.05
Calmar ratio Return relative to maximum drawdown	-0.31	-0.36	+0.05
Martin ratio Return relative to average drawdown	-0.48	-0.79	+0.31
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

AUTL vs. ATRA - Sharpe Ratio Comparison

The current AUTL Sharpe Ratio is -0.13, which is comparable to the ATRA Sharpe Ratio of -0.19. The chart below compares the historical Sharpe Ratios of AUTL and ATRA, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	AUTL	ATRA	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.13	-0.19	+0.05
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.32	-0.51	+0.19
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	-0.39	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.39	-0.31	-0.08

Correlation

The correlation between AUTL and ATRA is 0.26, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

AUTL vs. ATRA - Dividend Comparison

Neither AUTL nor ATRA has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

AUTL vs. ATRA - Drawdown Comparison

The maximum AUTL drawdown since its inception was -97.63%, roughly equal to the maximum ATRA drawdown of -99.74%. Use the drawdown chart below to compare losses from any high point for AUTL and ATRA.

Drawdown Indicators

	AUTL	ATRA	Difference
Max Drawdown Largest peak-to-trough decline	-97.63%	-99.74%	+2.11%
Max Drawdown (1Y) Largest decline over 1 year	-54.85%	-76.89%	+22.04%
Max Drawdown (5Y) Largest decline over 5 years	-85.68%	-99.16%	+13.48%
Max Drawdown (10Y) Largest decline over 10 years	—	-99.68%	—
Current Drawdown Current decline from peak	-97.13%	-99.70%	+2.57%
Average Drawdown Average peak-to-trough decline	-80.90%	-73.60%	-7.30%
Ulcer Index Depth and duration of drawdowns from previous peaks	35.18%	34.94%	+0.24%

Volatility

AUTL vs. ATRA - Volatility Comparison

The current volatility for Autolus Therapeutics plc (AUTL) is 21.17%, while Atara Biotherapeutics, Inc. (ATRA) has a volatility of 38.92%. This indicates that AUTL experiences smaller price fluctuations and is considered to be less risky than ATRA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	AUTL	ATRA	Difference
Volatility (1M) Calculated over the trailing 1-month period	21.17%	38.92%	-17.75%
Volatility (6M) Calculated over the trailing 6-month period	56.49%	115.23%	-58.74%
Volatility (1Y) Calculated over the trailing 1-year period	82.98%	110.45%	-27.47%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	79.19%	113.89%	-34.70%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	81.05%	95.60%	-14.55%

Financials